Ocular Complications From Cancer Therapy - Patient Registry and Biobank

Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Mar 7, 2025

Keywords

ClinConnect Summary

This clinical trial, called "Ocular Complications From Cancer Therapy," aims to gather important information about patients who have experienced eye problems after receiving cancer treatments. Researchers at the University of Maryland will collect details about patients' medical and eye histories, past treatments, and any surgical procedures they may have had. To better understand the causes of these eye issues, they will also collect samples like eye wash and blood. The goal is to improve knowledge of how cancer therapies can affect the eyes and potentially find better ways to help patients.

To participate, you must be an adult over 18 years old and either have undergone cancer treatment (like chemotherapy or stem cell transplants) or be a healthy adult with no history of cancer. Participants will be recruited during their eye doctor visits, where they will receive a standard eye examination and provide consent to join the study. It’s important to know that the trial is not yet recruiting participants, but it will include individuals of all genders. If you or someone you know is interested, keeping an eye out for when the study starts could be beneficial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria for the Cancer Therapy Group:
• • Adult patients (greater than 18 years of age)
• • Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery)
• • Patients who have a history of allogenic HSCT with all stem cell sources including bone marrow, PBSC, cord AND/OR patients with a history of prior cancer therapy including BMT, chemotherapy, and immunotherapy
• • Patients will be recruited after their HSCT or cancer therapy at their ophthalmology appointment
• • Patients can be included with a history of prior cancer therapy including chemotherapy, BMT, immunotherapy. Prior cancer therapy must be identified and documented.
• • The patient must be able to understand and sign and date the informed consent form approved by the IRB.
• Inclusion Criteria for the Control Group:
• • No history of cancer or cancer therapy in the past
• • Adult patients (greater than 18 years of age)
• • Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery)
• • The patient must be able to understand and sign and date the informed consent form approved by the IRB.
• Exclusion Criteria for the Cancer Therapy Group:
• • Vulnerable populations: neonates, children, prisoners, institutionalized individuals
• • Inability or refusal to provide informed consent.
• • History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma).
• Exclusion Criteria for the Control Group:
• • Vulnerable populations: neonates, children, prisoners, institutionalized individuals
• • Inability or refusal to provide informed consent.
• • History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma).
• • History of cancer or cancer therapy including chemotherapy, immunotherapy, BMT.